Free Trial
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

Verona Pharma plc (VRP.L) logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
55
55
52-Week Range
N/A
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
Aggregate Rating
N/A

ETF Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

VRP ETF News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Verona Pharma price target raised to $72 from $44 at Canaccord
Verona Pharma Keeps Hitting New Highs
See More Headlines

VRP ETF - Frequently Asked Questions

Verona Pharma plc (VRP.L) (LON:VRP) posted its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share for the quarter, beating analysts' consensus estimates of ($30.80) by $0.50.

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (LON:VRP) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners